Does radioiodine therapy in patients with differentiated thyroid cancer increase the frequency of another malignant neoplasm?

Página do item simplificado
dc.contributor.authorHirosawa, Renata Midori [UNESP]
dc.contributor.authorMarivo, Monica
dc.contributor.authorLuengo, Juliana de Moura Leite
dc.contributor.authorTagliarini, Jose Vicente
dc.contributor.authorCastilho, Emanuel Cellice
dc.contributor.authorMarques, Mariangela de Alencar
dc.contributor.authorKiy, Yoshio
dc.contributor.authorMarone, Marilia Martins Silveira
dc.contributor.authorSilveira, Liciana Vaz de Arruda
dc.contributor.authorMazeto, Glaucia Maria Ferreira da Silva
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-12-07T15:30:04Z
dc.date.available2015-12-07T15:30:04Z
dc.date.issued2011
dc.description.abstractObjectives. To compare the frequency of another primary malignancy in patients with differentiated thyroid carcinoma (DTC) who received radioiodine therapy or not ((131)I). Material and Methods. 168 cases of DTC patients were retrospectively evaluated as to the frequency of another neoplasia by comparing patients with and without it, taking into account clinical, laboratory, and therapeutic parameters. Results. Another primary malignancy occurred in 8.9% of patients. Of these, 53.3% showed the malignancy before (131)I and 46.7% after it. By comparing both groups, the age at the moment of diagnosis of another neoplasia was 46.1 ± 20.2 years for the group before (131)I therapy and of 69.4 ± 11.4 years for the group after it (P = 0.02). Of the 148 patients treated with (131)I, 4.7% developed another malignancy. The latter were older (61 ± 17 years) than those who did not show another cancer type (44.1 ± 14.2 years) (P < 0.05). Conclusion. The frequency of another neoplasia found after (131)I was similar to that found before (131)I.en
dc.description.affiliationDepartamento de Clinica Medica, Faculdade de Medicina (FMB), UNESP, Rubiao Junior s/n, Botucatu, 18618-000 São Paulo, Brazil.
dc.description.affiliationUnespDepartamento de Clinica Medica, Faculdade de Medicina (FMB), UNESP, Rubiao Junior s/n, Botucatu, 18618-000 São Paulo, Brazil.
dc.identifierhttp://dx.doi.org/10.5402/2011/708343
dc.identifier.citationIsrn Oncology, v. 2011, 2011.
dc.identifier.doi10.5402/2011/708343
dc.identifier.filePMC3200138.pdf
dc.identifier.issn2090-567X
dc.identifier.pmcPMC3200138
dc.identifier.pubmed22084737
dc.identifier.urihttp://hdl.handle.net/11449/130902
dc.language.isoeng
dc.publisherIsrn Oncology
dc.relation.ispartofIsrn Oncology
dc.rights.accessRightsAcesso aberto
dc.sourcePubMed
dc.titleDoes radioiodine therapy in patients with differentiated thyroid cancer increase the frequency of another malignant neoplasm?en
dc.typeArtigo
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt
unesp.departmentClínica Médica - FMBpt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
PMC3200138.pdf
Tamanho:
1.16 MB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Botucatu - FMB - Faculdade de Medicina